GLP-1 Medications: The Complete Guide for Women

How GLP-1 medications work

GLP-1 (glucagon-like peptide-1) is a gut hormone your intestines release after meals. It tells your pancreas to produce insulin, slows how quickly food leaves your stomach, and signals fullness at the hypothalamus. Natural GLP-1 has a half-life of just a few minutes. GLP-1 receptor agonists — engineered peptides that bind the same receptor — last about a week, which is why they are once-weekly injections.

The mechanism operates on four fronts simultaneously:

• Appetite suppression at hypothalamic and mesolimbic reward centers. Most patients describe this as the "food noise" turning down.
• Delayed gastric emptying. Meals sit in the stomach longer; you feel full sooner and stay full longer.
• Improved insulin sensitivity. Particularly relevant for women in perimenopause and menopause, whose insulin resistance rises with estrogen decline.
• Preferential visceral-fat reduction. Imaging studies show GLP-1s reduce deep abdominal fat — the metabolically dangerous kind — more than subcutaneous fat.

For a mechanism-level explainer, see our companion piece on what peptides are and how they differ from small-molecule drugs.

The three GLP-1 medications that matter

Three molecules dominate the category in 2026. All are peptides. All are weekly subcutaneous injections. The differences are in how many receptors they hit and how large the average weight loss is.

Semaglutide

A single GLP-1 receptor agonist. Sold as Ozempic (FDA-approved for type 2 diabetes), Wegovy (FDA-approved for chronic weight management), and Rybelsus (oral, diabetes only). The molecule is identical across the injectables; only the indication and maximum dose differ. Compounded semaglutide is available through licensed 503A pharmacies when clinically justified. Deep dive: semaglutide for weight loss.

Tirzepatide

A dual GIP/GLP-1 receptor agonist — meaning it activates a second incretin receptor (GIP) alongside GLP-1. In head-to-head trials it produces larger average weight loss than semaglutide with a comparable side-effect profile. Sold as Mounjaro (diabetes) and Zepbound (weight). See our full tirzepatide guide.

Retatrutide (investigational)

A triple agonist hitting GLP-1, GIP, and glucagon receptors. Phase 2 data (Jastreboff et al., 2023 NEJM) reported 24.2% average weight loss at 48 weeks at 12 mg — the largest reduction ever recorded from a weight medication. Not yet FDA-approved; approval is expected 2027. Not currently prescribed at Kindr Health.

Standard dosing schedules

Both semaglutide and tirzepatide are titrated slowly to minimize gastrointestinal side effects. The FDA-approved schedules below are starting points; your physician may titrate more slowly if you have significant GI sensitivity, low body weight, or perimenopausal nausea.

Semaglutide (Wegovy)

Tirzepatide (Zepbound)

The clinical goal is the lowest effective dose, not the maximum dose. Many women reach their weight-loss target at 1.0–1.7 mg semaglutide or 7.5–10 mg tirzepatide.

Realistic results for women

Trial averages set expectations, but individual response varies. The pivotal randomized trials showed:

• STEP-1 (semaglutide 2.4 mg, 68 weeks): average 14.9% body-weight reduction versus 2.4% on placebo. About a third of participants lost ≥20%. (Wilding et al., NEJM, 2021)
• SURMOUNT-1 (tirzepatide 15 mg, 72 weeks): average 20.9% body-weight reduction versus 3.1% on placebo. (Jastreboff et al., NEJM, 2022)
• Retatrutide phase 2 (12 mg, 48 weeks): average 24.2% body-weight reduction. (Jastreboff et al., NEJM, 2023)

In practice, women in perimenopause and menopause at Kindr Health typically see:

• 3–6 lb in month 1 (mostly water and appetite reset)
• 1–2 lb per week during months 2–6 as the dose escalates
• 12–20% total loss by month 9–12 with consistent dosing and resistance training
• Waist-circumference reduction that outpaces scale weight, because visceral fat drops first

See why menopause causes weight gain for the underlying biology.

Side effects and how we manage them

Nausea, constipation, and reflux are by far the most common side effects. They peak in weeks 1–2 and at each dose escalation, and resolve for most patients by week 6–8. Escalating more slowly nearly always fixes them.

• Nausea — smaller meals, hydration, ginger, slower titration.
• Constipation — 25–35 g fiber daily, 400 mg magnesium glycinate at night, water.
• Reflux — smaller meals, avoid eating within 3 hours of bed, elevate head of bed.
• Fatigue / lightheadedness — often electrolyte-driven; sodium and potassium support helps.
• Hair shedding — usually rapid-loss related, not the drug. Resolves with adequate protein and slower loss pace.
• Gallbladder issues and pancreatitis — uncommon but serious. Report severe abdominal pain immediately.

Contraindications: personal or family history of medullary thyroid carcinoma, MEN-2 syndrome, active pancreatitis, or active gallbladder disease. GLP-1s are absolute contraindications in pregnancy and breastfeeding. Wash out for at least 2 months before conception.

The under-discussed side effect: muscle loss

Without intervention, 25–40% of total weight lost on GLP-1s comes from lean mass (Wilding et al., 2021; Ida et al., 2023). Because muscle is your primary site of glucose disposal and the biggest contributor to resting metabolic rate, losing it accelerates metabolic slowdown after stopping the drug — and predicts weight regain.

The fix is protocolized:

• Protein: 1.2–1.6 g per kg body weight daily (a 150 lb woman = ~85–110 g). Front-load breakfast — appetite is highest early in the day on GLP-1s.
• Resistance training: full-body twice weekly, minimum. Progressive overload matters more than volume.
• Creatine monohydrate: 3–5 g daily. One of the most-studied supplements in the world; particularly effective in women over 40.
• Vitamin D and adequate sleep — both directly affect muscle protein synthesis.

kindr GLP-1 Complete is the in-house muscle-preservation supplement stack designed for exactly this scenario. See also creatine for women.

Why GLP-1s are uniquely effective in menopause

Between roughly age 40 and 55, estrogen decline drives a metabolic shift that diet alone rarely reverses:

• Fat storage moves from hips and thighs to the abdomen (visceral fat).
• Insulin sensitivity drops. Fasting insulin rises. Blood sugar becomes less stable.
• Resting metabolic rate falls roughly 50–100 kcal per day per decade after 40.
• Sleep disruption from vasomotor symptoms further impairs glucose control.

GLP-1s address three of those four levers directly: appetite, insulin sensitivity, and visceral fat. This is why women in perimenopause and menopause frequently see body-composition improvements on GLP-1s that they could not achieve with any diet or exercise intervention in their 30s.

Related reading: menopause weight gain, cortisol and menopause, and collagen in menopause.

Combining GLP-1s with hormone therapy

GLP-1s do not interact pharmacologically with estradiol, progesterone, or testosterone. They can be prescribed alongside hormone therapy and are increasingly used that way in midlife women. The combination often produces better body-composition outcomes than either alone: HRT restores lean-mass-preserving signals from estrogen; the GLP-1 addresses appetite, insulin, and visceral fat.

One practical note: slowed gastric emptying can affect the absorption of oral medications taken with meals. This does not clinically affect transdermal estradiol or vaginal estrogen. Oral hormone therapy timing may occasionally need to be adjusted; your clinician will review this at intake.

Cost, insurance, and legitimate sourcing

Three legal categories exist in 2026:

1. Brand (Wegovy, Zepbound, Ozempic, Mounjaro). FDA-approved. Cash price roughly $1,000–$1,350/month. Many commercial insurance plans cover Wegovy or Zepbound with prior authorization for BMI ≥30 or ≥27 with a comorbidity. Ozempic and Mounjaro are typically restricted to type 2 diabetes.
2. 503A compounded semaglutide or tirzepatide. Prepared by a licensed compounding pharmacy under a specific physician prescription when clinically justified for the patient. Legal but not FDA-approved as a drug product. Typically $250–$500/month. Kindr Health uses 503A pharmacies that source FDA-registered active pharmaceutical ingredient.
3. "Research" peptides sold online. Not legal for human use, no quality verification, frequent contamination. Kindr Health does not source from these suppliers under any circumstance.

For the difference between compounded and research-grade peptides, see compounded peptides explained and are peptides safe.

How to get a GLP-1 prescription online

Kindr Health prescribes semaglutide and tirzepatide via 100% online physician evaluation in all 50 U.S. states. The intake is designed to be thorough enough that your clinician has real clinical information — not a rubber stamp.

1. Complete the online medical intake (about 10 minutes).
2. Baseline labs: A1c, fasting insulin, lipid panel, TSH, CBC, comprehensive metabolic panel, vitamin D.
3. Video or async visit with a board-certified physician licensed in your state.
4. If clinically appropriate, prescription is sent to a licensed partner pharmacy and shipped discreetly.
5. Monthly clinician check-ins. Lab rechecks at 3 and 6 months.
6. Structured taper and maintenance protocol when the goal weight is reached.

See plans and pricing for the prescription pathway, or start with the metabolic reset integrated program if hormone care and GLP-1 are both on the table.

Frequently asked questions

Sources

1. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989–1002. (STEP-1)
2. Rubino D et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance. JAMA. 2021;325(14):1414–1425. (STEP-4)
3. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205–216. (SURMOUNT-1)
4. Jastreboff AM et al. Triple–hormone-receptor agonist retatrutide for obesity. N Engl J Med. 2023;389(6):514–526.
5. Lincoff AM et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221–2232. (SELECT)
6. Ida S et al. Effects of GLP-1 receptor agonists on lean mass. Obes Res Clin Pract. 2023;17(3):203–210.
7. Davis SR et al. Menopause. Nat Rev Dis Primers. 2015;1:15004.
8. The 2022 Hormone Therapy Position Statement of The North American Menopause Society. Menopause. 2022;29(7):767–794.

Medical disclaimer. This guide is educational and does not constitute medical advice. GLP-1 medications are prescription only and require physician evaluation. Individual results and eligibility depend on your medical history and clinical findings. Contraindications include personal or family history of medullary thyroid carcinoma, MEN-2 syndrome, pancreatitis, pregnancy, and breastfeeding. Medically reviewed by the Kindr Health Clinical Team. Last reviewed 2026-06-10.

Latest from the Journal

• GLP-1 + Weight

  Muscle Loss on GLP-1: What the Research Shows

  GLP-1 medications cause 25–40% of weight loss to come from lean mass. Here is what the data actually says and the three-part protocol that protects muscle.

  Read Muscle Loss on GLP-1: What the Research Shows →